Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF Read more about Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF
A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies Read more about A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma Read more about An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States Read more about ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States
A Phase 1, Study of BMF-500 in Adults With Acute Leukemia Read more about A Phase 1, Study of BMF-500 in Adults With Acute Leukemia
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab Read more about Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia Read more about A Study of SNDX-5613 in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia